anyone have thoughts on ARDM?
lot of similarities in terms of the basic technology and market opportunities.
most glaring difference seems that ARDM is not currently funded.
but the valuation disparity is enormous.
INSM ev= $229 mil
ARDM ev=$28 mil
INSM would be smart to buy this company. It will be within reach in a year. That way they could use the patent to put Cipro into the INSM liposome and have the absolutely "no mutation will lower therapeutic effect" rotation of two antibiotics drugs against Pa. They would literally drive all the other inhalation drugs off the market except liposome Tobrymycin, which would also fit into the rotation. Remember the science - lipids break the biofilm and are sucked up by the macrophages. Get as many antibiotics inside a lipid formulation and treat every infectious agent that gets into the lungs. No one has even mentioned the orphan lung infeictions that involve molds, fungi and spores.
Have you ever heard the phrase: "it takes money to make money?" I seem to remember ARDM from a long time ago, but obviously these two companies are headed in opposite directions. And you underestimated INSM by about 100 million as I type.